ASTELLAS PHARMA EUROPE LTD.
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Subsidiary
- Employees
- -
- Market Cap
- -
- Website
- http://www.astellas.com/eu
A Survey About Trade-offs When Choosing Menopause Treatments
Completed
- Conditions
- Moderate to Severe Vasomotor Symptoms
- First Posted Date
- 2022-03-29
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- Astellas Pharma Europe Ltd.
- Target Recruit Count
- 1465
- Registration Number
- NCT05300568
- Locations
- 🇬🇧
Site GB44001, Hammersmith, United Kingdom
A Survey About Hot Flashes in Women Going Through the Menopause
Completed
- Conditions
- Vasomotor SymptomsMenopause
- First Posted Date
- 2021-10-19
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- Astellas Pharma Europe Ltd.
- Target Recruit Count
- 2176
- Registration Number
- NCT05083884
- Locations
- 🇬🇧
IQVIA, London, United Kingdom
A Study to Evaluate the ePidemiology of anEmia Associated With chroNic Kidney Disease in Patients in Primary Care Using The Stockholm CREAtinine Measurement (SCREAM) Register
Completed
- Conditions
- Chronic Kidney Disease
- First Posted Date
- 2021-08-23
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Astellas Pharma Europe Ltd.
- Target Recruit Count
- 45637
- Registration Number
- NCT05015998
- Locations
- 🇸🇪
SE46001, Stockholm, Sweden
Retrospective Analysis Assessing Clinical Risk Factors for Cardiovascular Events and Mortality and Development of a Risk Calculator in Chronic Kidney Disease Stage 5 on Dialysis
Completed
- Conditions
- Chronic Kidney Disease (CKD)
- First Posted Date
- 2019-08-01
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Astellas Pharma Europe Ltd.
- Target Recruit Count
- 2773
- Registration Number
- NCT04042350
- Locations
- 🇸🇪
Site SE46001, Uppsala, Sweden
A Non-Interventional Study to Evaluate Time to Event and Healthcare Resource Utilisation for Prostate Cancer Participants Throughout the Disease Trajectories Until Progression or Death
Completed
- Conditions
- Prostate Cancer
- First Posted Date
- 2018-08-08
- Last Posted Date
- 2025-01-13
- Lead Sponsor
- Astellas Pharma Europe Ltd.
- Target Recruit Count
- 6908
- Registration Number
- NCT03619980
- Locations
- 🇸🇪
Site SE46001, Uppsala, Sweden
A Study to Compare the Finger Prick Whole Blood MITRA Assay Method With the Established Venepuncture Whole Blood Method for Quantitative Determination of Tacrolimus Blood Concentrations in Transplant Patients
- First Posted Date
- 2018-03-15
- Last Posted Date
- 2018-10-15
- Lead Sponsor
- Astellas Pharma Europe Ltd.
- Target Recruit Count
- 80
- Registration Number
- NCT03465969
- Locations
- 🇫🇷
Site FR33002, Toulouse, France
🇫🇷Site FR33001, Villejuif, France
🇬🇧Site UK44002, Cambridge, United Kingdom
Study to Evaluate the Safety and Pharmacokinetics of Single Doses of ASP2151 in Healthy Male Subjects and the Effects of Food
- First Posted Date
- 2016-08-02
- Last Posted Date
- 2016-08-02
- Lead Sponsor
- Astellas Pharma Europe Ltd.
- Target Recruit Count
- 72
- Registration Number
- NCT02852876
- Locations
- 🇫🇷
Site FR1717, Paris, France
Global, Multicentre, Non Interventional Advagraf Conversion Registry in Kidney Transplant Patients
- First Posted Date
- 2015-09-22
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Astellas Pharma Europe Ltd.
- Target Recruit Count
- 4430
- Registration Number
- NCT02555787
- Locations
- 🇦🇺
Site AU6107, Camperdown, New South Wales, Australia
🇦🇺Site AU6106, Gosford, New South Wales, Australia
🇦🇺Site AU6104, New Lambton, New South Wales, Australia
European Observational Study of Enzalutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)
- First Posted Date
- 2015-07-13
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- Astellas Pharma Europe Ltd.
- Target Recruit Count
- 1763
- Registration Number
- NCT02495974
- Locations
- 🇦🇹
Site AT43001, Bregenz, Austria
🇦🇹Site AT43005, Innsbruck, Austria
🇦🇹Site AT43006, Linz, Austria
Study to Evaluate the Pharmacokinetics of Fidaxomicin in Inflammatory Bowel Disease (IBD) Subjects With Clostridium Difficile Infection (CDI)
Phase 4
Completed
- Conditions
- Inflammatory Bowel Disease (IBD)Clostridium Difficile Infection (CDI)
- Interventions
- First Posted Date
- 2015-05-07
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Astellas Pharma Europe Ltd.
- Target Recruit Count
- 25
- Registration Number
- NCT02437591
- Locations
- 🇦🇹
Site AT43001, Graz, Austria
🇫🇷Site FR33002, Clichy, France
🇫🇷Site FR33001, Paris, France